BML-277

CAS No. 516480-79-8

BML-277( BML-277 | C 3742 | Checkpoint Kinase 2 Inhibitor II )

Catalog No. M14798 CAS No. 516480-79-8

BML-277 (C 3742) is a selective Chk2 (checkpoint kinase 2) inhibitor with an IC50 of 15 nM.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 49 In Stock
2MG 29 In Stock
5MG 45 In Stock
10MG 73 In Stock
25MG 151 In Stock
50MG 259 In Stock
100MG 368 In Stock
200MG 538 In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    BML-277
  • Note
    Research use only, not for human use.
  • Brief Description
    BML-277 (C 3742) is a selective Chk2 (checkpoint kinase 2) inhibitor with an IC50 of 15 nM.
  • Description
    BML-277 (C 3742) is a selective Chk2 (checkpoint kinase 2) inhibitor with an IC50 of 15 nM.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    BML-277 | C 3742 | Checkpoint Kinase 2 Inhibitor II
  • Pathway
    Angiogenesis
  • Target
    Chk
  • Recptor
    Chk2
  • Research Area
    Cancer
  • Indication
    ——

Chemical Information

  • CAS Number
    516480-79-8
  • Formula Weight
    363.8
  • Molecular Formula
    C20H14ClN3O2
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO: 10 mM
  • SMILES
    O=C(C1=CC=C2C(N=C(C3=CC=C(OC4=CC=C(Cl)C=C4)C=C3)N2)=C1)N
  • Chemical Name
    2-(4-(4-Chlorophenoxy)phenyl)-1H-benzimidazole-5-carboxamide

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Arienti KL, et al. J Med Chem. 2005 Mar 24; 48(6): 1873-85.
molnova catalog
related products
  • MK 8776

    MK 8776 (SCH 900776) is a potent and functionally selective CHK1 inhibitor (IC50=3 nM) with minimal intrinsic antagonistic properties.

  • CCT-244747

    A novel, potent, highly selective, orally active, ATP competitive CHK1 inhibitor with biochemical IC50 of 8 nM; displays 75-fold selectivity against FLT3 and >1,000-fold selectivity against CHK2 and CDK1.

  • LY2880070

    LY2880070 is a new checkpoint kinase 1 (CHK1) inhibitor for cancer therapy.